Trade TARS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Tarsus Pharmaceuticals, Inc. (TARS) is trading at US$71.70, down 0.31% today as of Aug 28, 13:58 EDT. The company has a market capitalisation of US$3.19B. Over the past 52 weeks, TARS has traded between US$48.20 and US$85.25. On Syfe you can trade TARS with $0 commission and add it to your watchlist.
| Previous close | US$71.92 |
|---|---|
| Market cap | US$3.19B |
| P/E ratio | 452.39 |
| 52-week range | US$48.20 – US$85.25 |
| Volume | 565.94K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Year: 2020
RxSight Names Aziz Mottiwala as CEO
Jul 15, 8:43 PM · MT Newswires
Tarsus Pharmaceuticals, Inc. (TARS) stock is trading at US$71.70, -0.31% from the previous close of US$71.92.
The market cap for Tarsus Pharmaceuticals, Inc. (TARS) stock is approximately US$3.19B.
The price-to-earnings ratio for Tarsus Pharmaceuticals, Inc. (TARS) is 452.39, based on the latest reported earnings.
The 52-week high for Tarsus Pharmaceuticals, Inc. (TARS) stock is US$85.25.
The 52-week low for Tarsus Pharmaceuticals, Inc. (TARS) stock is US$48.20.
Tarsus Pharmaceuticals, Inc. (TARS) does not currently pay a dividend.
Stay on top of TARS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
